Omeros (NASDAQ:OMER) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Several other analysts also recently weighed in on OMER. UBS Group assumed coverage on shares of Omeros in a research note on Monday, February 1st. They issued a “buy” rating and a $25.00 price target for the company. HC Wainwright lowered their price objective on shares of Omeros from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Monday, May 3rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $22.50.
OMER opened at $18.43 on Wednesday. The company has a fifty day moving average price of $18.24 and a 200-day moving average price of $16.74. The firm has a market capitalization of $1.15 billion, a P/E ratio of -7.74 and a beta of 1.65. Omeros has a one year low of $9.25 and a one year high of $25.46.
Omeros (NASDAQ:OMER) last released its quarterly earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, meeting analysts’ consensus estimates of ($0.57). The firm had revenue of $21.10 million for the quarter, compared to analysts’ expectations of $21.96 million. The business’s quarterly revenue was down 10.6% on a year-over-year basis. Research analysts forecast that Omeros will post -1.97 earnings per share for the current year.
In related news, CAO Michael A. Jacobsen sold 10,000 shares of the firm’s stock in a transaction on Friday, February 19th. The shares were sold at an average price of $22.64, for a total transaction of $226,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 24,000 shares of the company’s stock, valued at $543,360. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Gregory A. Md Demopulos sold 72,613 shares of Omeros stock in a transaction on Thursday, April 8th. The stock was sold at an average price of $17.84, for a total transaction of $1,295,415.92. Following the completion of the transaction, the chief executive officer now directly owns 2,064,393 shares of the company’s stock, valued at $36,828,771.12. The disclosure for this sale can be found here. Insiders sold 90,713 shares of company stock worth $1,710,384 over the last quarter. Insiders own 11.30% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in OMER. Sonora Investment Management LLC boosted its stake in shares of Omeros by 81.7% during the 4th quarter. Sonora Investment Management LLC now owns 6,540 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,940 shares during the period. Nwam LLC lifted its holdings in Omeros by 2.3% during the 4th quarter. Nwam LLC now owns 26,395 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 600 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Omeros by 4,965.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 29,584 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 29,000 shares in the last quarter. Calton & Associates Inc. raised its holdings in shares of Omeros by 11.8% in the 4th quarter. Calton & Associates Inc. now owns 14,806 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 1,557 shares in the last quarter. Finally, National Asset Management Inc. raised its holdings in shares of Omeros by 13.2% in the 4th quarter. National Asset Management Inc. now owns 17,716 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 2,068 shares in the last quarter. 56.63% of the stock is owned by hedge funds and other institutional investors.
Omeros Company Profile
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: What is a price target?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Return on Investment (ROI)
If you’re an investor that likes to go with the “hot hand,” then they don’t get much hotter than Cathie Wood. The founder and CEO of ARK Investment Management delivered returns of over 100% in all five of her firm’s exchange-traded funds (ETFs) in 2020.
The names of her funds showcase some of the hottest emerging growth trends in the market: financial technology (fintech), genomic revolution, innovation, autonomous technology/robotics, and next generation internet.
As you would expect, these funds contain some of the hottest growth stocks from the past year. And in the aftermath of the tech selloff, Wood is not backing away. In fact, she’s doubling down on her strategy. It might not be exactly a matter of being greedy while others are fearful; perhaps more like being prepared while others are distracted.
But the other thing about Wood’s selections is that many of them are not obscure names. These are companies that were among the hottest names in 2020. Wood simply believes that they still have room to run. And that’s one reason you should consider making them a part of your portfolio.
In this special presentation, we’re giving you just seven of the stocks that Cathie Wood is buying or has bought recently. We’ve attempted to pick out at least one stock from each of the ARK ETFs. As with any investment decision, it’s important that you perform your own research before making a decision.